Skip to main content

ACNS1723 A Phase 2 Study of Dabrafenib (NSC# 763760) with Trametinib (NSC# 763093) after Local Irradiation in Newly Diagnosed BRAFV600-Mutant High-Grade Glioma (HGG) (IND# 145355)

NCT03919071

A Phase 2 Study of Dabrafenib (NSC# 763760) with Trametinib (NSC# 763093) after Local Irradiation in Newly Diagnosed BRAFV600-Mutant High-Grade Glioma (HGG) (IND# 145355)

Associated Conditions

Brain Cancer

Principal Investigator

Sponsor

Children's Oncology Group

The study doctors want to see if using dabrafenib and trametinib after radiation treatment will be better than treatments used in the past in helping to get rid of or shrink HGGs. Dabrafenib works by blocking protein (a basic building block of the human body) called BRAF that lets cancer cells grow without stopping. Trametinib works similarly by blocking another protein called MEK that allows cancer cells to grow without stopping. The overall goal of this study is to find out what effects, good and/or bad, dabrafenib and trametinib have on people with HGG.

This study is currently enrolling.